HENGRUI PHARMA (01276) has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the SHR-7012 injection, paving the way for clinical trials to commence in the near future.
The SHR-7012 injection, an innovative drug independently developed by the company, is intended for the treatment of cutaneous lupus erythematosus. According to available research, no drugs targeting the same pathway have been approved for marketing domestically or internationally to date.
As of now, the cumulative research and development investment in the SHR-7012 injection project amounts to approximately RMB 25.5 million (unaudited).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.